Akouos

Akouos is a biotechnology company focusing on restoring and preserving hearing. The company leverages adeno-associated viral (AAV) vector-based gene therapy in order to restore and preserve hearing in genetically-defined patient populations in a range of forms, from a single genetic mutation to ototoxic drug exposure and to the aging process, enabling the healthcare industry to treat sensorineural hearing loss in an efficient manner.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Eli Lilly

INDIANAPOLIS , Dec. 1, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Akouos, Inc. (NASDAQ: AKUS). The acquisition expands Lilly's efforts in genetic medicines to include Akouos's portfolio of potential first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss.

Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases

INDIANAPOLIS and BOSTON , Nov. 30, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Akouos, Inc. (NASDAQ: AKUS) today announced that the tender offer to purchase all of the issued and outstanding shares ("Shares") of Akouos's common stock in exchange for (a) $12.50 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (b) one non-tradable contingent value right ("CVR") per Share, which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones (the "Offer"), expired as scheduled at one minute past 11:59 p.m., Eastern time, on Nov. 29, 2022 and was not extended (such date and time, the "Expiration Time").

Lilly and Akouos Announce Expiration of Akouos Tender Offer

-Received clearance from FDA for the AK-OTOF IND application to initiate a Phase 1/2, first in human, pediatric clinical trial

Akouos Reports Third Quarter 2022 Financial Results and Provides Business Highlights

ACM Research

Biohaven Pharmaceutical Hld

Cano Health

FingerMotion

Immunovant Inc

Ngm Biopharmaceuticals Inc

Nutex Health Inc

Tango Therapeutics

TuSimple Holdings

Small-cap stocks can offer big returns in a short period of time, especially when the economy is rebounding from a slowdown.

These Were the Five Best and Worst Performing Small-cap Stocks in October 2022

NEW YORK , Oct. 24, 2022 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Akouos, Inc. (AKUS), relating to its proposed acquisition by Eli Lilly and Company. Under the terms of the tender offer, AKUS shareholders are expected to receive $12.50 in cash plus one CVR of up to $3.00 per share they own.

INVESTOR ALERT: The M&A Class Action Firm Announces the Investigation of Akouos, Inc. - AKUS

NEW YORK , Oct. 21, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Akouos, Inc. ("Akouos" or the "Company") (NASDAQ: AKUS), in connection with the proposed tender offer for the Company by Eli Lilly and Company (NYSE: LLY).  Under the tender offer, the Company's shareholders will receive $12.50 in cash, plus one contingent value right ("CVR") of up to $3.00 per share for each share of Akouos common stock owned.

SHAREHOLDER ALERT: Weiss Law Investigates Akouos, Inc.

Akouos (AKUS) is set to be acquired by Eli Lilly for an aggregate amount of $610 million. The deal is expected to close in the fourth quarter of 2022.

Akouos (AKUS) Surges on $610M Buyout Deal With Eli Lilly

Eli Lilly and Company (LLY) announced it is buying Akouos (AKUS) in a $610 million deal. These are the details.

Why Lilly (LLY) Is Buying Akouos (AKUS) For $610 Million

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C.

AKOUOS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akouos, Inc. - AKUS

Wilmington, Delaware--(Newsfile Corp. - October 18, 2022) - Rigrodsky Law, P.A. is investigating Akouos, Inc. ("Akouos") (NASDAQ GS: AKUS) regarding possible breaches of fiduciary duties and other violations of law related to Akouos' agreement to be acquired by Eli Lilly and Company. Under the terms of the agreement, Akouos' shareholders will receive $12.50 per share plus one contingent value right ("CVR"), which represents the contractual right to receive contingent payments up to $3.00 per CVR.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Akouos, Inc. Merger

There's notable merger news today as pharmaceutical giant Eli Lilly (NYSE: LLY ) entered into a definitive agreement to acquire Akouos (NASDAQ: AKUS ). Clearly, Eli Lilly is looking to expand further into gene therapies.

Why Is Akouos (AKUS) Stock Up 85% Today?

MILWAUKEE , Oct. 18, 2022 /PRNewswire/ -- Ademi LLP is investigating Akouos (NASDAQ: AKUS) for possible breaches of fiduciary duty and other violations of law in its transaction with Eli Lilly.  Click here to learn how to join the action https://www.ademilaw.com/case/akouos-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Akouos, Inc. has obtained a Fair Price in its transaction with Eli Lilly

A buyout agreement is lighting a fire underneath the biotech's shares today.

Why Akouos Stock Is on Fire Today

The merger hopes to accelerate advances in gene therapies that help patients with hearing loss.

Akouos Stock Soars as Eli Lilly Buys Genetic Therapies Company for $610 Million

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Akouos, Inc. (NASDAQ: AKUS) to Eli Lilly and Company is fair to Akouos shareholders.

AKUS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akouos, Inc. Is Fair to Shareholders

Drugmaker Eli Lilly and Co will acquire genetic medicine developer Akouos Inc in a cash deal worth about $487 million.

Eli Lilly to buy genetic medicine developer Akouos for $487 million

Eli Lilly and Co. LLY, +0.41% said Tuesday it has entered an agreement to acquire Akouos Inc. AKUS, -5.14% , a company developing a portfolio of viral gene therapies for the treatment of inner ear conditions including hearing loss, for up to $610 million in cash. Under the terms of the deal, Akouos shareholders will receive $12.50 a share in cash, plus one non-tradeable contingent value right per share that entitles the holder to receive up to an additional $3.00 in cash, for a total consideration of up to $15.50 per share in cash without interest, or an aggregate of $610 million.

Eli Lilly to acquire Akouos for up to about $610 million and develop gene therapies for hearing loss

Proposed acquisition will accelerate gene therapies that aim to restore, improve, and preserve hearing for patients living with disabling hearing loss worldwide Transaction valued at approximately $487 million plus a contingent value right for an aggregate amount up to approximately $610 million INDIANAPOLIS and BOSTON , Oct. 18, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Akouos, Inc. (NASDAQ: AKUS) today announced a definitive agreement for Lilly to acquire Akouos, a precision genetic medicine company that is developing a portfolio of first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss. "We are honored to work with the talented team at Akouos who are breaking new ground in the science of treating hearing loss," said Andrew C.

Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss

Akouos, Inc. (AKUS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Akouos, Inc. (AKUS) Upgraded to Strong Buy: Here's Why

-The IND for AK-OTOF is the first to receive FDA clearance for a genetic form of hearing loss and the first for an AAV vector therapy with the potential to treat an inner ear condition

Akouos Receives FDA Clearance of its IND Application for AK-OTOF, a Gene Therapy Intended for the Treatment of OTOF-mediated Hearing Loss

Akouos, Inc. (AKUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Akouos, Inc. (AKUS) Upgraded to Buy: Here's Why

BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today reports financial results for the second quarter ended June 30, 2022 and provides business highlights.

Akouos Reports Second Quarter 2022 Financial Results and Provides Business Highlights

- Nonclinical data demonstrate that a single intracochlear administration of an AAVAnc80 vector led to durable restoration of auditory function and was well tolerated, supporting planned clinical development of AK-OTOF for the treatment of OTOF-mediated hearing loss

Akouos Presents Nonclinical Data Supporting the Planned Clinical Development of AK-OTOF and Strategies for Regulated Gene Expression in the Inner Ear at the American Society of Gene and Cell Therapy 25th Annual Meeting

- Continued progress toward planned IND submissions for AK-OTOF in the first half of 2022 and AK-antiVEGF in 2022

Akouos Reports First Quarter 2022 Financial Results and Provides Business Highlights

BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, will participate in a presentation at the Bank of America 2022 Healthcare Conference on Tuesday, May 10 at 10:00 a.m. PDT in Las Vegas, Nevada.

News for Akouos Stock (AKUS)